Clinically meaningful rates of functional cure in patients with chronic hepatitis B infection treated with bepirovirsen: B-well phase 3 trials

Background and aims: Functional cure (FC), hepatitis B surface antigen (HBsAg) loss and hepatitis B virus (HBV) DNA 100–≤3000 IU/mL were randomised 2:1 to bepirovirsen 300 mg or placebo weekly for 24 weeks. Participants discontinued NAs at Week 48, if eligible. The primary outcome was FC response rate at Week 72 for all participants; defined as HBsAg not detected (qualitative;<0.05 IU/mL) and HBV DNA